Delayed or lost net new business awards
CRO revenue depends on winning sponsor programs; delays or cancellations directly reduce backlog and utilization.
- Scope
- Clinical Services pipeline and contract conversion
- Materiality
- high
Fortrea Holdings Inc.
Fortrea Holdings Inc. is a standalone contract research organization created from Labcorp’s drug development business in 2023. It designs and runs clinical development programs for pharmaceutical, biotechnology, and medical device customers, spanning phase I through IV trials, clinical pharmacology, and consulting services.
−29,2 %
−36,2 %
+1,0 %
0.98
0.98
| % | |
|---|---|
| Clinical Development Services | 70% End-to-end planning, execution, and management of clinical trials across phases I-IV. |
| Clinical Pharmacology | 15% Specialized early-stage development services supporting dose selection and human pharmacology studies. |
| Functional Service Provider (FSP) | 10% Dedicated functional outsourcing teams that support specific sponsor functions and workflows. |
| Consulting and Advisory | 5% Protocol, regulatory, operational, and development strategy support for sponsors. |
Fortrea sells to pharmaceutical, biotechnology, and medical device companies that need outsourced clinical development...
- Pharmaceutical companiesprimary
Buy full-service and functional outsourcing for late-stage and global clinical programs to accelerate development.
- Biotechnology companiesprimary
Buy flexible, high-touch clinical development and pharmacology support to advance pipelines with limited internal infrastructure.
- Medical device companiessecondary
Buy clinical trial management and consulting for regulated device development and evidence generation.
- Small and emerging sponsorssecondary
Buy scientific, regulatory, and operational support to design studies and execute trials efficiently.
- Large biopharma sponsorsprimary
Buy scalable global delivery, FSP teams, and hybrid structures for complex multi-country programs.
Fortrea operates in approximately 100 countries and says it supports trials in all major pharmaceutical and...
- •Operations span approximately 100 countries
- •Trials run across major pharma and biotech markets
- •Workforce split: 26% Americas, 27% EMEA, 47% Asia-Pacific
- •Global footprint supports site access and patient recruitment
- •International mix creates FX and regulatory execution exposure
Fortrea’s strategy centers on commercial excellence, operational excellence, and financial excellence, with an emphasis...
01
Grow repeat business and new awardsshort-term
Clinical CRO revenue depends on winning and retaining sponsor programs, which can be delayed or reduced in scope.
02
Improve operational execution and marginsmedium-term
Better study delivery, site performance, and centralized processing can improve profitability in a service-heavy model.
03
Strengthen therapeutic and geographic capabilitiesmedium-term
Broader expertise and global reach help win complex trials and support customer geographic priorities.
Fortrea’s results depend on sponsor funding, trial award timing, patient recruitment, and investigator availability, so...
Patient recruitment and investigator access constraints
Trials cannot progress without suitable sites and enrolled patients, which can push out timelines and revenue recognition.
- Scope
- Phase I-IV trial execution
- Materiality
- high
International operating complexity
Operating in about 100 countries creates exposure to local regulation, currency movements, and geopolitical disruptions.
- Scope
- Global delivery footprint
- Materiality
- high
Customer and therapeutic concentration
A small number of large sponsors or therapeutic areas can disproportionately affect demand and margins if programs change.
- Scope
- Sponsor mix and therapeutic portfolio
- Materiality
- medium
Integration and acquisition execution
Strategic transactions can create disruption, goodwill impairment risk, and operational complexity if not integrated well.
- Scope
- M&A and divestiture activity
- Materiality
- medium
Revenue recognition on clinical service contracts
Affects reported growth, margins, and comparability across periods
Discontinued operations
Impacts year-over-year comparability and segment analysis
Goodwill impairment
Could create material noncash charges if fair value declines
Receivables securitization
Influences working capital, cash flow, and leverage optics
: 28.4.2026